Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells f
Go back to Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells f| Xenetic Biosciences, Inc. (NASDAQ: XBIO) | Delayed: 1.93 -0.09 (4.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.02 | 52 Week High | $5.20 | |||
| Open | $2.03 | 52 Week Low | $0.21 | |||
| Day High | $2.04 | P/E | N/A | |||
| Day Low | $1.90 | EPS | $-0.01 | |||
| Volume | 18,881 | |||||



